HMDB 3.0—The Human Metabolome Database in 2013

David S. Wishart(University of Alberta), Timothy Jewison(Centre international de recherche sur le cancer), An Chi Guo(Centre international de recherche sur le cancer), Michael Wilson(Centre international de recherche sur le cancer), Craig Knox(Centre international de recherche sur le cancer), Yifeng Liu(Centre international de recherche sur le cancer), Yannick Djoumbou-Feunang(University of Alberta), Rupasri Mandal(Centre international de recherche sur le cancer), Farid Aziat(University of Alberta), Edison Dong(Centre international de recherche sur le cancer), Souhaila Bouatra(University of Alberta), Igor Sinelnikov(University of Alberta), David Arndt(Centre international de recherche sur le cancer), Jianguo Xia(University of Alberta), Philip L.‐F. Liu(Centre international de recherche sur le cancer), Faizath S. Yallou(Centre international de recherche sur le cancer), Trent C. Bjorndahl(Centre international de recherche sur le cancer), Rolando Pérez(Centre international de recherche sur le cancer), Roman Eisner(Centre international de recherche sur le cancer), Felicity Allen(Centre international de recherche sur le cancer), Vanessa Neveu(Centre international de recherche sur le cancer), Russell Greiner(Centre international de recherche sur le cancer), Augustin Scalbert(Centre international de recherche sur le cancer)
Nucleic Acids Research
November 17, 2012
Cited by 2,902Open Access
Full Text

Abstract

The Human Metabolome Database (HMDB) (www.hmdb.ca) is a resource dedicated to providing scientists with the most current and comprehensive coverage of the human metabolome. Since its first release in 2007, the HMDB has been used to facilitate research for nearly 1000 published studies in metabolomics, clinical biochemistry and systems biology. The most recent release of HMDB (version 3.0) has been significantly expanded and enhanced over the 2009 release (version 2.0). In particular, the number of annotated metabolite entries has grown from 6500 to more than 40,000 (a 600% increase). This enormous expansion is a result of the inclusion of both 'detected' metabolites (those with measured concentrations or experimental confirmation of their existence) and 'expected' metabolites (those for which biochemical pathways are known or human intake/exposure is frequent but the compound has yet to be detected in the body). The latest release also has greatly increased the number of metabolites with biofluid or tissue concentration data, the number of compounds with reference spectra and the number of data fields per entry. In addition to this expansion in data quantity, new database visualization tools and new data content have been added or enhanced. These include better spectral viewing tools, more powerful chemical substructure searches, an improved chemical taxonomy and better, more interactive pathway maps. This article describes these enhancements to the HMDB, which was previously featured in the 2009 NAR Database Issue. (Note to referees, HMDB 3.0 will go live on 18 September 2012.).


Related Papers

No related papers found

Powered by citation graph analysis